Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ICOS Corporation -- Ignore unavailable to you. Want to Upgrade?

To: Icebrg who wrote (1007)	10/9/2003 9:30:23 PM
From: SemiBull	Respond to of 1139

ICOS to Manufacture Clinical Candidate for Protein Design Labs Thursday October 9, 9:14 am ET BOTHELL, Wash.--(BUSINESS WIRE)--Oct. 9, 2003--ICOS Corporation (Nasdaq:ICOS - News) today announced that it has entered into a manufacturing agreement with Protein Design Labs, Inc. (PDL) (Nasdaq:PDLI - News), a biopharmaceutical company based in Fremont, Calif. Under the terms of the agreement, ICOS will manufacture PDL's M200, an antibody currently in Phase 1 clinical studies. The antibody was initially developed by Eos Biotechnology, Inc. and manufactured by ICOS for early-stage clinical trials. The manufacturing campaign is to be conducted during the first half of 2004. "We are pleased that Protein Design Labs, a company recognized for their commitment to antibody development, has chosen ICOS to continue the production of their clinical material," stated Gary Wilcox, Ph.D., Executive Vice President, Operations of ICOS. Brett Schmidli, Senior Vice President, Technical Operations, PDL, said, "ICOS' scale of operation, the noteworthy track record of their manufacturing unit and quality systems make them our choice for manufacturing M200's initial Phase 2 trial requirements. With a number of our products already in clinical development, PDL's near-term production flexibility is limited until our expanded production facilities can accommodate M200." About ICOS biologics manufacturing capabilities: For over 10 years, ICOS has conducted process development and cGMP clinical manufacturing to support its pipeline development and that of its corporate partners. For the last three years, ICOS has also provided cell line, process development and manufacturing services for other biotechnology and pharmaceutical companies. The Company has produced multiple novel therapeutic agents for Phase 1 through Phase 3 clinical studies. The ICOS clinical manufacturing facility, located in Bothell, Washington, houses areas designed for cGMP production and purification of both cell culture and microbial fermentation products. It can accommodate microbial fermentation up to 1,600 L and cell culture production up to 3,000 L. The facility is supported by highly experienced Process Development, Manufacturing, QA, QC and Engineering personnel. Additional information on ICOS' process development and cGMP clinical manufacturing is available at icosbiologics.com. About ICOS Corporation: ICOS is a product-driven company that has expertise in both protein-based and small molecule therapeutics. ICOS combines its capabilities in molecular, cellular and structural biology, high throughput drug screening, medicinal chemistry and gene expression profiling to develop highly innovative products expected to have significant commercial potential. ICOS applies its integrated approach to erectile dysfunction and other urologic disorders, sepsis and other inflammatory diseases. ICOS' strategy targets multiple therapeutic areas with drugs that act through distinct molecular mechanisms, increasing ICOS' opportunities to market breakthrough products. This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve risks and uncertainties that could cause ICOS' results and the timing of certain events to differ materially from those discussed in the forward-looking statements, including risks associated with clinical development, regulatory approvals, product commercialization, intellectual property claims and litigation and other risks detailed in ICOS' latest Annual Report on Form 10-K and its other SEC filings. Contact: ICOS Corporation Lacy Fitzpatrick, 425-415-2207 Source: ICOS Corporation